Abstract 260P
Background
MOGCT is rare tumors and represent 2% of all tumors of the ovary. Fertility preserving surgery is the standard of care for pts with MOGCT. Comprehensive surgical staging involves unilateral adnexectomy, omentectomy, peritoneal biopsies, washings and lymph node sampling. Visual inspection has been suggested as an alternative. Proposed surgical approach includes complete resection of the tumor-containing ovary with sparing of fallopian tube, inspection and palpation of contralateral ovary, omentum, lymph nodes, and peritoneum, biopsy of any suspicious lesions or lymph nodes, and collection of peritoneal washing or ascites. The objective of the study was to describe the clinico-pathologic features and treatment outcome of all patients diagnosed with MOGCT at the largest Russian Research Cancer Center.
Methods
A total of 149 pts treated for MOGCT in our center between 1987-2018 were included into this retrospective study. All data including clinical symptoms, demographics, stage, surgery, chemotherapy, survival and fertility function were analyzed and assessed in univariate and multivariate analysis. The median age was 22 years (range, 12-49 years). 109 (73.2%) of 149 underwent fertility-sparing surgery followed by chemotherapy (ChT). Histologically 29.5% (n = 44) of cases were pure dysgerminoma. All pts received BEP/EP regimens as a first line treatment. 14 (9.4%) pts had gonadal dysgenesis.
Results
With median follow-up of 86 mo. (range 1-337 mo.) 5-year OS was 92%. The 5-year disease free survival (DFS) was 87% (9.4% pts relapsed). The 5-year DFS in pts with dysgerminoma and non-dysgerminoma was 98% and 91% respectively (p = 0,2). The 5-year OS in pts with stage I was 100% and stages II-IV was 91%. Complete response reached in 97 (67.3%) of 144 assessed pts, marker-negative partial response registered in 34 (23.6%) pts. After first-line ChT completion 34/144 (23.6%) pts underwent surgical resection of residual masses.
Conclusions
The BEP regimen is a standard of care and provides high cure rate. Fertility-sparing surgery is standart volume of surgery even in advanced stages of disease. The BEP regimen does NOT adversely affect on fertility function of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
381P - XKR8 is a promising potential prognostic marker in glioblastoma multiforme patients
Presenter: Kristina Havrysh
Session: Poster display session
Resources:
Abstract
383P - Screening of prognostic molecular biomarker for resectable pancreatic cancer
Presenter: Yonggang Peng
Session: Poster display session
Resources:
Abstract
384P - Prevalence of abnormal microsatellite instability test among ovary and endometrial cancer patients
Presenter: Min Kyu Kim
Session: Poster display session
Resources:
Abstract
385P - Identifying CASP8 polymorphisms associated with breast cancer risk in an Iranian population
Presenter: Alireza Pasdar
Session: Poster display session
Resources:
Abstract
386P - Unusual folding of NaPi2b transporter extramembrane domain 4 during malignant transformation
Presenter: Leysan Minigulova
Session: Poster display session
Resources:
Abstract
387P - 5-years conditional disease free survival and overall survival for breast cancer patients in South Korea
Presenter: Jee hyun Ahn
Session: Poster display session
Resources:
Abstract
388P - To identify circulating tumour cells by machine learning approach
Presenter: Yuebin Liang
Session: Poster display session
Resources:
Abstract
389P - The establishment of patient-derived organoid models and drug response of resectable non-small cell lung cancer
Presenter: Jing-Hua Chen
Session: Poster display session
Resources:
Abstract
395P - Filipinos and lung cancer: An infodemiological assessment using Google trends from 2009 to 2019
Presenter: Lance Isidore Catedral
Session: Poster display session
Resources:
Abstract
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract